Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia
© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U..
Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in kidney transplant (KT) patients are limited to some published cases.
Methods: We performed a retrospective observational study that included all KT patients admitted between August 1st, 2020 and December 31st, 2020 with SARS-CoV-2 pneumonia who received remdesivir.The objective of this study was to describe the experience of a cohort of KT patients treated with remdesivir.
Discussion: A total of 37 KT patients developed SARS-CoV-2 infection, 7 of them received treatment with remdesivir. The rest of the patients did not receive the drug due to either CKD-EPI less than 30 mL/min or they did not present clinical criteria. In addition to remdesivir, all patients received dexamethasone and anticoagulation therapy. 4 were men, the median age was 59 (53-71) years. Median time from transplantation was 43 (16-82) months. Chest X-rays of all patients showed pulmonary infiltrates and required low-oxygen flow therapy upon admission, requiring high-flow nasal therapy in 3 cases. Only 2 cases presented deterioration of the graft function, not requiring hemodialysis in any case, and all recovered renal function at hospital discharge. 2 patients rise up 1.5 times the liver function test. No patient died or required admission to the critical care unit. Median days of admission was 12 (9-27) days.
Conclusions: Our study suggests that the use of remdesivir could be useful in KT patients with SARS-CoV-2 pneumonia without side effects. Additional studies are necessary with a larger number of patients to improve the knowledge of this drug in SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - 42(2022), 3 vom: 01. Mai, Seite 311-317 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Remdesivir en pacientes trasplantados renales con neumonía por SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Cacho, Judit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney failure |
|---|
| Anmerkungen: |
Date Revised 24.10.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.nefro.2021.05.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32850050X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32850050X | ||
| 003 | DE-627 | ||
| 005 | 20231225203043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.nefro.2021.05.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM32850050X | ||
| 035 | |a (NLM)34305226 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Cacho, Judit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia |
| 246 | 3 | 3 | |a Remdesivir en pacientes trasplantados renales con neumonía por SARS-CoV-2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. | ||
| 520 | |a Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in kidney transplant (KT) patients are limited to some published cases | ||
| 520 | |a Methods: We performed a retrospective observational study that included all KT patients admitted between August 1st, 2020 and December 31st, 2020 with SARS-CoV-2 pneumonia who received remdesivir.The objective of this study was to describe the experience of a cohort of KT patients treated with remdesivir | ||
| 520 | |a Discussion: A total of 37 KT patients developed SARS-CoV-2 infection, 7 of them received treatment with remdesivir. The rest of the patients did not receive the drug due to either CKD-EPI less than 30 mL/min or they did not present clinical criteria. In addition to remdesivir, all patients received dexamethasone and anticoagulation therapy. 4 were men, the median age was 59 (53-71) years. Median time from transplantation was 43 (16-82) months. Chest X-rays of all patients showed pulmonary infiltrates and required low-oxygen flow therapy upon admission, requiring high-flow nasal therapy in 3 cases. Only 2 cases presented deterioration of the graft function, not requiring hemodialysis in any case, and all recovered renal function at hospital discharge. 2 patients rise up 1.5 times the liver function test. No patient died or required admission to the critical care unit. Median days of admission was 12 (9-27) days | ||
| 520 | |a Conclusions: Our study suggests that the use of remdesivir could be useful in KT patients with SARS-CoV-2 pneumonia without side effects. Additional studies are necessary with a larger number of patients to improve the knowledge of this drug in SARS-CoV-2 infection | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute kidney failure | |
| 650 | 4 | |a Kidney transplantation | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Burgos, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, María |e verfasserin |4 aut | |
| 700 | 1 | |a Villegas, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Cañas, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Taco, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Juega, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Lauzurica, Ricardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia |d 1994 |g 42(2022), 3 vom: 01. Mai, Seite 311-317 |w (DE-627)NLM082760829 |x 0211-6995 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:3 |g day:01 |g month:05 |g pages:311-317 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nefro.2021.05.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 3 |b 01 |c 05 |h 311-317 | ||